Drugmaker Natco Pharma has received seven observations from the United States Food and Drug Administration following an inspection of its pharmaceutical manufacturing plant in Hyderabad. The American regulator conducted the inspection at the company’s formulation manufacturing unit in Kothur between November 12 and November 20, 2026. Regulatory concerns were recorded across seven points in Form 483 issued after the review. However, the company has described these observations as procedural in nature and expressed confidence in addressing all issues comprehensively within the stipulated timeline.
In a regulatory filing to the stock exchanges on November 21, Natco Pharma stated that it is preparing its response to all the points raised during the inspection. The company noted that it will take the necessary corrective measures to resolve the concerns highlighted by the American regulator.
Inspection of the Kothur Manufacturing Unit
The USFDA inspected Natco Pharma’s formulation manufacturing facility located in Kothur, Hyderabad, from November 12 to November 20. This plant manufactures finished pharmaceutical products. During the inspection, officials from the American regulator examined production and related processes at the site.
Following the examination, seven observations were issued to the company under Form 483. However, Natco Pharma did not disclose the detailed contents of these seven observations in its stock exchange filing. Consequently, it remains unclear which specific processes or systems were questioned by the regulator during the audit.
Understanding USFDA Form 483
A Form 483 is issued by the United States Food and Drug Administration to document conditions or procedural deficiencies observed during the inspection of a manufacturing facility that may indicate potential violations of regulatory requirements.
This form does not in itself constitute a final regulatory action or a ban against a company, nor is it directly considered a warning letter. Instead, the concerned company is asked to submit a response along with a corrective action plan addressing the observations noted during the inspection.
The company is required to outline the steps it will take to rectify the identified deficiencies and explain its plan to prevent such situations from recurring in the future. Based on the company’s response and available evidence, the regulator may then decide on further course of action.
Company Confident of Timely Resolution
Natco Pharma has stated that it views all seven observations issued by the USFDA as procedural in nature. The company remains confident that by working comprehensively on every point, the required improvements will be completed within the prescribed timeframe.
However, the company has not clarified the exact nature of the procedural gaps flagged in the seven observations, nor has it provided specific details regarding the proposed corrective steps. As a result, attention will now remain focused on the company’s formal reply and the regulator’s subsequent response.
Headquartered in Hyderabad, Natco Pharma develops and manufactures generic and branded medicines, specialty pharmaceuticals, and active pharmaceutical ingredients. Apart from the Indian domestic market, the company’s products reach several international markets.
Various manufacturing facilities of the company hold approvals from multiple regulatory bodies, including the USFDA, Brazil’s ANVISA, Health Canada, and the World Health Organization. For Indian pharmaceutical companies supplying medicines to the American market, strict adherence to USFDA quality standards is essential. Responding promptly to inspection observations and implementing necessary corrective actions is critical for sustaining their international operations.
At present, Natco Pharma faces the task of resolving the seven observations satisfactorily. While the company has stated that it is confident of completing this process within the stipulated schedule, the final regulatory status regarding the plant inspection will depend on the response submitted by the company and further review by the USFDA.
